Welcome to our dedicated page for Lexaria Bioscien news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscien stock.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. (NASDAQ:LEXX, NASDAQ:LEXXW) is a global innovator in drug delivery technology, specializing in its patented DehydraTECH™ platform. This groundbreaking technology enhances the way active pharmaceutical ingredients (APIs) are absorbed into the bloodstream, offering faster onset times, improved bioavailability, and reduced side effects. DehydraTECH is applicable across a wide range of APIs, including cannabinoids, antiviral drugs, nicotine, and GLP-1 receptor agonists, making it a versatile solution in the pharmaceutical and biotechnology industries.
Core Technology: DehydraTECH™
DehydraTECH™ is a patented drug delivery formulation and processing platform that optimizes the oral delivery of APIs. By improving bio-absorption rates—up to 27 times higher for cannabinoids in some cases—and reducing onset times from hours to minutes, the technology addresses critical challenges in drug delivery. It has also demonstrated the ability to facilitate the transport of APIs across the blood-brain barrier, a significant advantage for treating neurological conditions.
Market Applications
Lexaria’s technology is particularly impactful in high-growth markets:
- GLP-1 Drugs: DehydraTECH has shown promise in enhancing the oral delivery of GLP-1 receptor agonists like semaglutide, liraglutide, and tirzepatide, which are used to treat diabetes, obesity, and cardiovascular diseases. By enabling oral formulations, Lexaria aims to replace the widely disliked injectable versions of these drugs.
- Neurological Disorders: The technology's ability to cross the blood-brain barrier positions it as a valuable tool in treating conditions like epilepsy and Alzheimer’s disease.
- Cannabinoids: DehydraTECH optimizes the delivery of cannabinoids for therapeutic applications, including pain management and seizure mitigation.
Business Model and Revenue Streams
Lexaria operates through four primary segments:
- Intellectual Property Licensing: The company licenses its technology to pharmaceutical and nutraceutical companies, generating recurring revenue.
- B2B Production: Lexaria produces DehydraTECH-enhanced formulations for business partners.
- Research and Development: The company conducts extensive R&D to expand its technology’s applications and validate its efficacy.
- Corporate Operations: This includes strategic planning and partnerships to drive growth.
Competitive Landscape
In the GLP-1 drug market, Lexaria competes with pharmaceutical giants like Novo Nordisk and Eli Lilly. However, its ability to deliver APIs effectively through oral formulations offers a distinct competitive edge. The company’s focus on reducing gastrointestinal side effects and improving patient compliance further strengthens its market position.
Intellectual Property
Lexaria boasts a robust intellectual property portfolio with 48 granted patents and numerous pending applications worldwide. These patents cover a wide range of applications, from epilepsy treatment to GLP-1 drug delivery, reinforcing the company’s authority in drug delivery innovation.
Research and Development
Lexaria operates a licensed in-house research laboratory, conducting preclinical and clinical studies to validate its technology. Recent studies have shown promising results in enhancing the performance of GLP-1 drugs, cannabinoids, and antiviral formulations. The company is also exploring new applications in cardiovascular and neurological health.
Geographical Reach
Lexaria generates revenue primarily from the United States and Canada, with plans to expand its global footprint through strategic partnerships and licensing agreements.
Conclusion
Lexaria Bioscience Corp. is at the forefront of drug delivery innovation, leveraging its patented DehydraTECH™ technology to address critical challenges in the pharmaceutical industry. By enabling more effective oral formulations, the company is poised to disrupt markets dominated by injectable drugs, offering significant benefits to patients and healthcare providers alike.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has filed a pre-Investigational New Drug (IND) meeting request with the FDA, successfully initiating communication regarding its DehydraTECH-CBD for hypertension treatment. The FDA confirmed receipt and set a target date of July 30, 2022 for follow-up, contingent on meeting specific conditions. This meeting aims to clarify Lexaria's IND-enabling development program ahead of a full IND application expected later in 2022 or early 2023. The hypertension market, valued at $28 billion, presents significant potential for Lexaria's innovative drug delivery technology.
Lexaria Bioscience Corp. (LEXXW, LEXX) has entered into a significant licensing agreement with Premier Wellness Science Co., Ltd. to utilize its DehydraTECH technology in the Japanese non-pharmaceutical market. Premier will make minimum payments of US$4,527,500 over five years to retain exclusivity, along with receiving royalty revenue from product sales. This partnership aims to address the booming Japanese CBD market, projected to exceed US$35 billion annually. Premier's parent company reported US$187 million in revenue for the first three quarters of 2021, signaling robust market potential.
Lexaria Bioscience Corp. announced the licensing of its DehydraTECH technology to Valcon Medical A/S, a European contract manufacturing organization. This license targets medical cannabis applications in the EU and UK. Lexaria is set to receive milestone fees and royalties from product sales, optimizing revenue potential as Valcon manufactures various cannabis products. Valcon's GMP certification enhances their credibility in the market. This collaboration aims to capitalize on the growing demand for effective medical cannabis solutions.
Lexaria Bioscience Corp. held its 2022 Annual Meeting on May 31, with 49.2% of shares represented. Key voting results included:
- Chris Bunka elected with 97.15% approval
- John Docherty elected with 87.25% approval
- Nicholas Baxter elected with 84.5% approval
- Ted McKechnie elected with 96.1% approval
- Albert Reese Jr. elected with 96.56% approval
- Davidson & Company LLP appointed as auditors with 98.77% approval
- Non-binding compensation approval for executives at 93.52%
- Directors' past actions ratified at 91.1%
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the receipt of its 25th patent for its DehydraTECH technology, specifically aimed at enhancing the delivery of antiviral drugs. The patent, No. 11,311,559, will be issued on April 26, 2022, validating the effectiveness of DehydraTECH in improving bioavailability. Studies show that antiviral drugs processed with this technology achieve peak blood concentrations double that of standard drugs. This patent reinforces Lexaria's commitment to innovation in drug delivery and enhances its patent portfolio across various countries.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has initiated a multi-week human clinical study, HYPER-H21-4, aimed at evaluating the effectiveness of DehydraTECH-CBD for reducing blood pressure and other clinical benefits. This randomized, double-blind study involves 60 participants and is designed to bolster Lexaria's chances for an Investigational New Drug application with the FDA. Preliminary results show no serious adverse events, indicating good tolerance of DehydraTECH-CBD. The hypertension market, valued at $28 billion, presents a significant opportunity for Lexaria's innovative treatment.
Lexaria Bioscience Corp. announced positive results from its pulmonary hypertension clinical study, HYPER-H21-3, showing DehydraTECH-CBD significantly reduced pulmonary artery systolic pressure (PASP) in male participants. The treatment demonstrated a 41% overall reduction in PASP (p=0.045) during hypoxic conditions, supporting further research efforts. Lexaria intends to utilize these findings to seek FDA approval for formal clinical testing in hypertension management. The global hypertension market, valued at $28 billion, presents a significant opportunity for DehydraTECH-CBD as a potential treatment option.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced a new human nicotine study, NIC-H22-1, set to commence this summer, involving a minimum of 36 participants. The double-blinded study aims to compare the performance of Lexaria's DehydraTECH-nicotine pouches against leading brands like ON! and Zyn, with a focus on pharmacokinetic data and subjective user experiences. Lexaria previously noted success in animal studies, showing a significant increase in nicotine absorption speed. The oral nicotine pouch market is projected to grow significantly, reaching $21.84 billion by 2027.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has entered into agreements with Altria to provide DehydraTECH powder-based nicotine formulations for evaluation. These agreements will be effective until March 31, 2023. Lexaria's DehydraTECH technology enhances the bio-absorption of active pharmaceutical ingredients, improving oral delivery by 5-10 times and reducing onset times from 1-2 hours to minutes. The company holds 24 patents and has over 50 pending worldwide. For further details, visit Lexaria's website.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has launched its epilepsy research program, EPIL-A21-1, which will evaluate the effectiveness of DehydraTECH-CBD against Epidiolex, the first FDA-approved CBD treatment for seizures. The necessary test articles have been prepared and delivered to a third-party lab for dosing. Research phases will include acute and chronic seizure models, starting in May/June, with results expected by Q3 2022. The program is fully funded through existing resources, underscoring Lexaria's commitment to advancing its drug delivery technology.
FAQ
What is the current stock price of Lexaria Bioscien (LEXXW)?
What is Lexaria Bioscience Corp. known for?
What is DehydraTECH™?
What markets does Lexaria target?
How does Lexaria generate revenue?
What are Lexaria's competitive advantages?
What is Lexaria’s role in the GLP-1 drug market?
How many patents does Lexaria hold?
Where does Lexaria operate?
What recent achievements has Lexaria made?
What is Lexaria’s vision for the future?
